Last reviewed · How we verify
NCT07134205
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Phase 3 trial testing JMT101 in Metastatic Colorectal Cancer (mCRC) in 252 participants. Not yet recruiting.
1 June 2027
Quick facts
| Lead sponsor | Shanghai JMT-Bio Inc. |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 252 |
| Start date | 1 October 2025 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 October 2028 |
Drugs / interventions tested
- JMT101
- Irinotecan (irinotecan) — full drug profile →
- Regorafenib — full drug profile →
Conditions studied
- Metastatic Colorectal Cancer (mCRC) — all drugs for Metastatic Colorectal Cancer (mCRC) →
Sponsor
Shanghai JMT-Bio Inc. — full company profile →
Who can join
Adults 18 to 75, any sex, with Metastatic Colorectal Cancer (mCRC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, open-label, multicenter, phase III clinical study. The aim is to evaluate the efficacy of JMT101 in combination with irinotecan in the third-line and beyond treatment of Metastatic Colorectal Cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07134205
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of JMT101
Trials testing the same drug.
- NCT06989671 — SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC · Phase 2 · not yet recruiting
- NCT06735391 — A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients · Phase 3 · recruiting
- NCT06319313 — Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer · Phase 2, PHASE3 · not yet recruiting
- NCT05132777 — Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer · Phase 2 · unknown
- NCT04448379 — Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer · Phase 1 · unknown
Other recruiting trials for Metastatic Colorectal Cancer (mCRC)
Currently open trials in the same condition.
- NCT06938971 — Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life · NA · recruiting
- NCT06922383 — A Clinical Study of Arfolitixorin in Patients With mCRC · Phase 1, PHASE2 · recruiting
- NCT06645236 — DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit · NA · recruiting
Other Shanghai JMT-Bio Inc. trials
Trials by the same sponsor.
- NCT07441460 — A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer · Phase 3 · recruiting
- NCT07472647 — SYS6090 Combination Therapy in Advanced Lung Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07384377 — JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed · Phase 3 · not yet recruiting
- NCT07419698 — Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants · Phase 1 · recruiting
- NCT07332533 — A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer · Phase 2, PHASE3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07134205 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai JMT-Bio Inc.
- Last refreshed: 21 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07134205.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing